Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.56 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.56 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.56 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.56 |
| ▸ | F10 | P00742 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | PPIA | P62937 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14086749 | 0.85 | PDK1 (0.53) | PDK1PDK2PDK3PDK4F10 | |
| SCHEMBL4255007 | 0.83 | PPIA (0.64) | PDK1PDK2PDK3PDK4F10 | |
| SCHEMBL4874500 | 0.81 | PDK1 (0.58) | PDK1PDK2PDK3PDK4F10 | |
| SCHEMBL13956782 | 0.80 | MEN1 (0.69) | PDK1PDK2PDK3PDK4MAOB | |
| SCHEMBL31202580 | 0.80 | RAB9A (0.55) | — | |
| SCHEMBL21497178 | 0.78 | MAOB (0.71) | PDK1PDK2PDK3PDK4F10 | |
| SCHEMBL29521694 | 0.76 | ALDH1A1 (0.68) | — | |
| SCHEMBL4873842 | 0.76 | EPHX2 (0.75) | — | |
| SCHEMBL5104712 | 0.76 | MEN1 (0.64) | PDK1PDK2PDK3PDK4F10 | |
| Trifluoroacetic Acid SCHEMBL20569263 | 0.75 | PDK1 (0.57) | PDK1PDK2PDK3PDK4NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| WO-2008073623-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | PDK1 1125/4885PDK2 1595/4885PDK3 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.